Douglas Earl Martin — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Douglas Earl Martin is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $40K.
Profile
Douglas Earl Martin is identified in SEC filings as the Senior Vice President and General Counsel of Allogene Therapeutics, Inc. as of the filing date of 2026-02-04. Based on the SEC context, his responsibilities likely encompass overseeing legal affairs, corporate governance, securities compliance, and intellectual property strategy for Allogene. The SEC document provides the name and title but does not furnish detailed biographical information such as education, career history, or prior roles. Name variants may include Douglas E. Martin or Doug Martin.
Role
SVP, General Counsel
Notability
60/100
Board memberships
Allogene Therapeutics, Inc.
Awards & honors
Listed as SVP, General Counsel in Allogene Therapeutics SEC filings
Douglas Earl Martin is identified in SEC filings as the Senior Vice President and General Counsel of Allogene Therapeutics, Inc. as of the filing date of 2026-02-04. Based on the SEC context, his responsibilities likely encompass overseeing legal affairs, corporate governance, securities compliance, and intellectual property strategy for Allogene. The SEC document provides the …
Has Douglas Earl Martin been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($40K) across all tracked filings.
Where can I see all of Douglas Earl Martin's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
